A newly developed fat loss drug might be the answer to your shredding woes.
On average, subjects in a study conducted by scientists at the University of Leeds in England, dropped 5kg over a 12-week period after receiving weekly doses of semaglutide, a drug currently in development by a Danish pharmaceutical company to treat diabetes.
“What was striking was the potency of the drug’s action,” says John Blundell, lead researcher in the study.
“We saw results in 12 weeks which may take as long as six months with other anti-obesity medication. The drug reduced hunger but also cravings for food and the sensation of wanting to eat — and these had previously been thought to stem from different parts of the brain.”
Semaglutide’s chemical structure is similar to the naturally-occuring hormone GLP-1 which is believed to act on the appetite control centre in the hypothalamus in the brain to reduce feelings of hunger.
According to Blundell the study, which was recently published in the journal Diabetes, Obesity and Metabolism, set out to probe whether the drug could also be manufactured to fight obesity by acting on the brain’s appetite control receptors.
“A drug that reduces daily food intake by about a quarter with a substantial reduction in body fat will help some people to feel more in control of their lives and will help to prevent the onset of poor health that often arises from obesity,” says Blundell.
Semaglutide is in the advanced stages of development and not yet available.